Benuvia, Texas Ibogaine to produce ibogaine in U.S.

Benuvia Operations, LLC and Texas Ibogaine Research Corporation have announced a collaboration to establish the production of pharmaceutical-grade ibogaine in the United States. This partnership aims to facilitate the domestic manufacture of ibogaine, a psychoactive compound under investigation for its potential in treating opioid use disorder and other conditions.

Partnership details

The collaboration between Benuvia and Texas Ibogaine Research Corporation marks a significant step towards establishing a reliable U.S. supply of pharmaceutical-grade ibogaine. This initiative seeks to support ongoing research and potential therapeutic applications of ibogaine by ensuring quality-controlled production within the country.

Regulatory context

Ibogaine is a psychoactive alkaloid derived from the root bark of the African shrub Tabernanthe iboga. It has been studied for its potential in treating opioid addiction, PTSD, and traumatic brain injury. However, its legal status varies globally, and it is not currently approved for medical use in the United States. The production of pharmaceutical-grade ibogaine domestically could influence future regulatory decisions.

Why it matters

The partnership between Benuvia and Texas Ibogaine Research Corporation could play a crucial role in advancing ibogaine research and development in the U.S. By establishing a domestic source of pharmaceutical-grade ibogaine, the collaboration may facilitate clinical trials and potentially pave the way for regulatory approval, offering new treatment options for conditions like opioid use disorder.

This development reflects growing interest in exploring alternative therapies for addiction and mental health conditions, highlighting the need for rigorous research and quality-controlled production.

For more information, visit the original source.